NeuBase Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q3 2018 to Q3 2022

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
NeuBase Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q3 2018 to Q3 2022.
  • NeuBase Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending September 30, 2022 was $29.2M, a 48.4% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2022 $29.2M +$9.53M +48.4% Sep 30, 2022 10-K 2022-12-21
Q3 2021 $19.7M +$10.9M +125% Sep 30, 2021 10-K 2022-12-21
Q3 2020 $8.76M +$4.7M +116% Sep 30, 2020 10-K 2021-12-23
Q3 2019 $4.06M +$4.05M +34026% Sep 30, 2019 10-K 2020-12-23
Q3 2018 $11.9K* Sep 30, 2018 10-K 2020-01-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.